Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Orchard Therapeutics Plc ADR (NQ: ORTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Orchard Therapeutics Plc ADR

< Previous 1 2 Next >
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
Eight presentations showcase the broad applicability of HSC gene therapy to address rare neurometabolic diseases and beyond 
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
One-time treatment with Lenmeldy has shown the potential to restore enzymatic function to stop or slow disease progression, with up to 12 years of follow-up (median 6.76 years) 
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
Three oral presentations and seven posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic diseases 
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps to resource ongoing and future launches of... 
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX
From Kahn Swick & Foti, LLC
Via Business Wire
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
New clinical data beyond previously reported neurological and skeletal results demonstrate favorable outcomes for multiple disease manifestations not effectively addressed by the current standard of... 
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SP® Plus Corporation (Nasdaq - SP), Orchard Therapeutics plc (Nasdaq - ORTX), Summit Materials (NYSE - SUM)
From Brodsky & Smith LLC
Via GlobeNewswire
Orchard Therapeutics PLC (NASDAQ: ORTX) Sets New 52-Week High in Thursday Session
Via Investor Brand Network
ORTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Orchard Therapeutics plc Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Kyowa Kirin to Acquire Orchard Therapeutics
From Orchard Therapeutics (Europe) Limited; Kyowa Kirin Co., Ltd.
Via GlobeNewswire
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial Results
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics to Present at Stifel’s Genetic Medicines Day
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDA
From Orchard Therapeutics (Europe) Limited
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.